Director Robert F. Williamson III filed a Form 4 with the SEC on November 18, 2026, disclosing a purchase of 25,000 shares of Perspective Therapeutics, Inc. common stock on November 17, 2026.

Key Highlights

  • Purchase date: November 17, 2026, with 25,000 shares of common stock acquired.
  • Weighted average price: $0.838 per share, with individual transaction prices ranging from $0.8200 to $0.8500, inclusive, according to the filing.
  • Acquiring entity: The shares were purchased indirectly through the RFW3 Revocable Trust.
  • Post-transaction indirect holdings: 53,473 shares held indirectly via the RFW3 Revocable Trust following the reported transaction.
  • Direct holdings: 115,271 shares held directly by the reporting person, as disclosed in the filing.
  • Reporting person role: Robert F. Williamson III is identified as a Director of Perspective Therapeutics, Inc.

Williamson's November 2026 Open-Market Purchase via RFW3 Revocable Trust

According to the Form 4 filed with the SEC, Robert F. Williamson III, a Director of Perspective Therapeutics, Inc. (NASDAQ:CATX), reported the acquisition of 25,000 shares of the company's common stock on November 17, 2026. The transaction was coded "P," indicating an open-market purchase. The shares were acquired indirectly through the RFW3 Revocable Trust at a weighted average price of $0.838 per share.

The filing notes in a footnote that the reported price is a weighted average, and that the shares were purchased across multiple transactions at prices ranging from $0.8200 to $0.8500, inclusive. The reporting person stated a willingness to provide full details of each separate transaction price to the issuer, any securityholder, or SEC staff upon request.

Following the reported purchase, Williamson's indirect beneficial ownership through the RFW3 Revocable Trust stood at 53,473 shares. The filing separately lists 115,271 shares held directly by the reporting person. No derivative securities transactions were reported. The Form 4 was signed on November 18, 2026, by Chris Nenno as Attorney-in-Fact for Williamson.

What Was Disclosed

Director Robert F. Williamson III disclosed a purchase of 25,000 shares of Perspective Therapeutics common stock through the RFW3 Revocable Trust on November 17, 2026, at a weighted average price of $0.838, leaving indirect holdings of 53,473 shares.